Efficacy and safety of copanlisib in relapsed/refractory B-cell non-Hodgkin lymphoma: A meta-analysis of prospective clinical trials

Overview of attention for article published in Frontiers in immunology, November 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (57th percentile)
Above-average Attention Score compared to outputs of the same age and source (64th percentile)

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 6 Dimensions

Readers on

mendeley: 19 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 55,019 followers.

Efficacy and safety of copanlisib in relapsed/refractory B-cell non-Hodgkin lymphoma: A meta-analysis of prospective clinical trials #lymphoma #lymsm https://t.co/wzFgNRh37A

28 Nov 2022

Reply Repost Favourite

RT @FrontImmunol: New Research: Efficacy and safety of copanlisib in relapsed/refractory B-cell non-Hodgkin lymphoma: A meta-analysis of pr…

12 Nov 2022

Reply Repost Favourite

Efficacy and safety of copanlisib in relapsed/refractory B-cell non-Hodgkin lymphoma: A meta-analysis of prospective clinical trials https://t.co/SW6rXz2xOw https://t.co/sAFBK5Xsal

12 Nov 2022

Reply Repost Favourite

New Research: Efficacy and safety of copanlisib in relapsed/refractory B-cell non-Hodgkin lymphoma: A meta-analysis of prospective clinical trials: Background Copanlisib is an intravenously administered pan-class I PI3K inhibitor that has… https://t.co/LC

11 Nov 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.